Overview
Concomitant, Sequential, and Standard Triple Therapy for H. Pylori Infection
Status:
Completed
Completed
Trial end date:
2013-10-01
2013-10-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To simultaneously compare the efficacies of 7-day triple, 10-day sequential and 7-day quadruple therapies for H. pylori infection in Taiwan. Consecutive H. pylori-infected patients were randomly assigned to a 7-day standard triple therapy (pantoprazole, clarithromycin, and amoxicillin for 7 days), a 10-day sequential therapy (pantoprazole and amoxicillin for 5 days, followed by pantoprazole, clarithromycin and metronidazole for a further 5 days) or a 7-day quadruple therapy (pantoprazole, clarithromycin, amoxicillin and metronidazole for 7 days). The end point is to evaluate the effectiveness of Helicobacter pylori eradication rates between three groups.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Kaohsiung Veterans General Hospital.Treatments:
Amoxicillin
Clarithromycin
Metronidazole
Pantoprazole
Criteria
Inclusion Criteria:- Consecutive H. pylori-infected outpatients, at least 20 years of age, with
endoscopically proven peptic ulcer diseases or gastritis
Exclusion Criteria:
- previous H. pylori-eradication therapy
- ingestion of antibiotics, bismuth, or proton pump inhibitors within the prior 4 weeks
- patients with allergic history to the medications used
- patients with previous gastric surgery
- the coexistence of serious concomitant illness (for example, decompensated liver
cirrhosis, uremia)
- pregnant women